Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P17931 (
galectin-3
)
2,860
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Psoriasis-specific proteins dysregulated in keratinocytes and involved in the pathophysiological process of psoriasis remains elusive. We report here that epidermal
galectin-3
expression is significantly downregulated in lesional skin, but not in non-lesional skin in psoriasis patients, nor in a group of diseases known as psoriasiform dermatitis clinically and histologically similar to psoriasis. The deficiency of epidermal
galectin-3
is sufficient to promote development of psoriatic lesions, as evidenced by more severe skin inflammation in
galectin-3
knockout (gal3
-/-
) mice, compared to wild-type mice, after imiquimod treatment, and in skin from gal3
-/-
mice grafted onto wildtype mice. The development of psoriatic-like lesions is attributable to 1) the spontaneously tuning up of psoriasis signatures in keratinocytes through JNK pathway; and 2) neutrophil accumulation caused by the enhanced leukocyte-recruiting capacity associated with overexpression of
S100A7
-9 and CXCL-1, 8 in keratinocytes with impaired
galectin-3
expression. Psoriasis-like skin inflammation is significantly improved in gal-3
-/-
mice both by inhibition of neutrophils accumulation with a selective CXCR2 antagonist of SB225002, and by intracutaneous injection of recombinant
galectin-3
. Overall, these findings offer promising
galectin-3
-related diagnostic and therapeutic resolutions of psoriasis.
...
PMID:Decrease of galectin-3 in keratinocytes: A potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis. 2916 25